Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | RARA | P10276 | 1/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.64 |
| ▸ | MTOR | P42345 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.61 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31124225 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL6473001 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL31124115 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL31124093 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL1561875 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL6473267 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL5383508 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL1262098 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL3442617 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT | |
| SCHEMBL31124203 | 1.00 | RARB (0.64) | RARBALDH1A1MEN1RARAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4692041-A1 | METHOD FOR PRODUCING BIO-DERIVED ESTER COMPOUND, BIO-DERIVED ESTER COMPOUND PRODUCED THEREBY, COSMETIC OR DETERGENT CONTAINING BIO-DERIVED ESTER COMPOUND, AND METHOD FOR REDUCING ODOR OF ESTER COMPOUND | ADEKA CORPORATION (JP) | 2026-02-11 | — | — | EP | disclosed |
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2025-06-26 | — | — | US | disclosed |
| EP-4499628-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2025-02-05 | — | — | EP | disclosed |
| US-12162834-B2 | Reactive mesogens | MERCK PATENT GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| WO-2024204392-A1 | METHOD FOR PRODUCING BIO-DERIVED ESTER COMPOUND, BIO-DERIVED ESTER COMPOUND PRODUCED THEREBY, COSMETIC OR DETERGENT CONTAINING BIO-DERIVED ESTER COMPOUND, AND METHOD FOR REDUCING ODOR OF ESTER COMPOUND | 株式会社ADEKA | 2024-10-03 | — | — | WO | disclosed |
| WO-2023180388-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERIVATIVES AS DEGRONS IN PROTACS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-09-28 | — | — | WO | disclosed |
| US-20220234988-A1 | REACTIVE MESOGENS | MERCK PATENT GMBH (DE) | 2022-07-28 | — | — | US | disclosed |
| EP-3963026-A1 | REACTIVE MESOGENS | Merck Patent GmbH (DE) | 2022-03-09 | — | — | EP | disclosed |
| CN-113785032-A | Reactive mesogen | 默克专利股份有限公司 | 2021-12-10 | — | — | CN | disclosed |
| WO-2020221677-A1 | REACTIVE MESOGENS | MERCK PATENT GMBH (DE) | 2020-11-05 | — | — | WO | disclosed |
| US-5641846-A | POLYMETHACRYLOYL MAIN CHAIN ACTING AS BACKBONE, AND BRANCHING OFF THERFORM, ATLEAST ONE COVALENTY BONDED PHOTOCHROMIC SIDE GROUP AND ATLEAST ONE NON-PHOTOCHROMIC SIDE GROUP; USED AS OPTICAL DATA STORAGE AND TRANSFER | BAYER AKTIENGESELLSCHAFT (DE) | 1997-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250205344-A1 | 2,4-DIOXOTETRAHYDROPYRIMIDINYL DERATIVES AS DEGRONS IN PROTACS | CRBN, AR, GNRHR | RARB 1535/4885ALDH1A1 3146/4885MEN1 1265/4885 |
| US-12162834-B2 | Reactive mesogens | BLM, MAS1, MCHR1 | RARB 481/4885ALDH1A1 4344/4885MEN1 1497/4885 |
| US-20220234988-A1 | REACTIVE MESOGENS | BLM, MAS1, MCHR1 | RARB 481/4885ALDH1A1 4344/4885MEN1 1497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.